Table 1.
Characteristics of the cohort
| Clinical variable | VEGF inhibitor (N=40) | No VEGF inhibitor (N=40) | P value for difference |
|---|---|---|---|
| Age, years | 61.8 (10.1) | 61.8 (9.6) | 0.98 |
| Nephrectomy, % | 83 | 68 | 0.12 |
| Prior HTN, % | 73 | 50 | 0.04 |
| Diabetes, % | 18 | 13 | 0.76 |
| ACE-I at sample, % | 36 | 23 | 0.21 |
| Female, % | 23 | 25 | 0.79 |
| Current smoking, % | 11 | 15 | 0.50 |
| Baseline systolic BP, mmHg | 126.7 (18.6) | 124.7 (16.6) | 0.49 |
| Baseline diastolic BP, mmHg | 74.3 (10.0) | 71.5 (9.0) | 0.52 |
| eGFR at urine collection, ml/min/1.73m2 | 60.3 (17.3) | 60.0 (18.7) | 0.64 |
| Days of treatment prior to collection* | 88 (39–183) | N/A |
HTN denotes hypertension; VEGF, vascular endothelial growth factor; ACE-I, Angiotensin converting enzyme inhibitor; BP, blood pressure.; eGFR, estimated glomerular filtration rate
Mean (SD) or % unless otherwise stated
*
Median (IQR)